Fig. 5From: Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastasesDifferentially gene expression analysis of matched primary lung tumors and brain metastases. (A) Heatmap of differentially expression genes. (B) Representative marker expression level comparison of cytotoxicity between matched primary lung tumors and brain metastases. (C) Representative chemokine expression level comparison between matched primary lung tumors and brain metastases. (D) Representative cytokine expression level comparison between matched primary lung tumors and brain metastases. (E) Representative immunoinhibitors expression level comparison between matched primary lung tumors and brain metastases. (F) Representative immunocostimulators expression level comparison between matched primary lung tumors and brain metastasesBack to article page